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Delusions are a difficult-to-treat and intellectually fascinating aspect of many psychiatric illnesses. Although scientific progress on
this complex topic has been challenging, some recent advances focus on dysfunction in neural circuits, specifically in those
involving dopaminergic and glutamatergic neurotransmission. Here we review the role of cholinergic neurotransmission in
delusions, with a focus on nicotinic receptors, which are known to play a part in some illnesses where these symptoms appear,
including delirium, schizophrenia spectrum disorders, bipolar disorder, Parkinson, Huntington, and Alzheimer diseases. Beginning
with what we know about the emergence of delusions in these illnesses, we advance a hypothesis of cholinergic disturbance in the
dorsal striatum where nicotinic receptors are operative. Striosomes are proposed to play a central role in the formation of delusions.
This hypothesis is consistent with our current knowledge about the mechanism of action of cholinergic drugs and with our abstract
models of basic cognitive mechanisms at the molecular and circuit levels. We conclude by pointing out the need for further
research both at the clinical and translational levels.
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INTRODUCTION
DSM-51,2 defines delusions as fixed beliefs that are not amenable
to change in light of conflicting evidence. Of note, the new edition
of DSM captured an important nuance, namely that it is the
dysfunctional process of belief, rather than its content necessarily
being false, which is significant. This definition highlights the
central differentiating aspects of delusions, which allow us to
identify them in the clinic and distinguish them from other kinds
of aberrant beliefs, including non-pathological ones: in particular,
the fixedness of the belief (conviction) and cultural non-
appropriateness (idiosyncrasy). Another important aspect of
delusional belief is its specificity: delusions tend to cluster into
certain themes, such as persecutory, grandiose, erotomanic, or
somatic. That these themes are constant across cultures suggests
an underlying biology. Furthermore, it has long been recognized
that there is a difference between somatic delusions—e.g.
Capgras, Fregoli, reduplication, or arguably, neglect syndromes,
in which the patient is often remarkably disinterested in
connecting to other beliefs and experiences—and the themed
delusions named previously.
Both hallucinations and delusions are present in many
neuropsychiatric illnesses. The classical definition of delusions as
false beliefs, and hallucinations as perceptions without corre-
sponding external stimuli, have been criticized as oversimplistic3.
Delusions only rarely occur in isolation from other psychotic
symptoms4, although this does occur in the so-called delusional
disorder2,5. Typically, research on delusions has focused on the
wide palette of schizophrenia spectrum disorders, but the basic
mechanisms of delusion formation are shared among multiple
disease states6. In particular, delusions occur in Alzheimer,
Parkinson, and Huntington diseases (HDs), delirium, post-ictal
states and bipolar disorder among others, different illnesses
presenting with a differential predominance of delusional themes
and duration of symptoms, and sometimes correlating with other
symptoms such as perceptual disturbances7.
Dysfunction of the dopaminergic system has traditionally been
assigned the central role in the pathogenesis of psychotic
symptoms8. In health, dopamine (DA) neurotransmission mediates
the motivational salience of environmental rewards. In psychosis,
salience appears not as a result of exogenous stimuli but rather
stems from “an endogenously driven assignment of novelty and
salience to stimuli”8,9. Anatomically, aberrant salience is mediated
by midbrain dopaminergic projections to mesocorticolimbic
areas8,9. It is for this reason that among the illnesses discussed
here, dementia in AD is particularly interesting, because it is
primarily a cholinergic disturbance10.
Somatic delusions frequently occur in psychotic patients where
they accrete more polythematic-like explanations, but they can
also occur outside a network of other delusional beliefs,
remarkably like the syndromes observed in neurological patients
with imageable lesions in their right frontal lobe11. The two-factor
hypothesis of delusions12–16 accounts for these differences and
puts forward a framework that synthesizes imaging work and
recent models of delusional thinking, focusing on right frontal
hypofunction and dorsal striatal hyperfunction, and accounting for
specific features of delusions.
The effects of antipsychotics on the reasoning bias (“jumping
to conclusions”, reduced belief flexibility, an externalized attribu-
tional style, and deficits in “theory of mind”) are well known.
Antipsychotics improve “theory of mind” and mainly belief
flexibility, with little effect on the “jumping to conclusions”
trait17. This review will not focus on the therapeutics of delusions
which include medications and special types of psychotherapy,
for which the reader is referred to an excellent review on the
subject18.
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THE MOLECULAR AND CIRCUIT LEVELS
Functional roles of the cholinergic system in mammalian cognitive
processes
Neuronal nicotinic acetylcholine receptors (nAChRs) are a hetero-
geneous family within the superfamily of pentameric ligand-gated
ion channels (pLGIC) that are expressed throughout the brain and
involved in a wide range of physiological and physiopathological
processes19–24. pLGIC include not only the neuronal subtype but
also the muscle-type nAChRs, γ-amino butyric acid (GABA)A,
glycine, and the 5-HT3 subtype of serotonin receptors.
Although brain nAChRs share a common structural architecture,
their cerebral localization, pharmacology, biophysical properties,
and developmental occurrence differ. The homomeric (α7 and α9)
or heteromeric (α2–α7 combined with β2–β4) nAChR subtypes
result from the combination of these subunits into pentameric
oligomers of ca. 270,000 Da (see reviews in refs 24,25). Through this
combinatorial procedure, Nature has developed abundant diver-
sity to fulfill connectomically and topologically distinct functional
requirements. Brain nAChRs have been classically associated with
excitatory neurotransmission26 and its modulation (see ref. 27), but
these are only fragmentary facets of their functional palette; their
cellular distribution along development and adulthood28,29 and
subcellular localization (predominantly presynaptic, but also
perisynaptic and postsynaptic30; reviewed in ref. 24) adds
complexity to this apparently primary role. Thus, nAChRs can
modulate the release of other neurotransmitters31,32, or acetylcho-
line (ACh) itself33–35, regulate synapse development36, cell
viability37, neurite outgrowth38 and brain energetic homeostasis39,
and modulate the establishment of functional networks during
neural development40 (see review in ref. 41), apparently affecting
the neuronal survival/death homeostasis. Because of their
strategic location in areas involved in memory acquisition,
maintenance and retrieval, nAChRs in hippocampus and cerebral
cortex play major roles in cognition and mnemonic functions42,43
and modulate prefrontal cortex functions related to conscious
processing44. All these phenomena are subject to dysfunction
under disease conditions (see below). At present, we probably
know only a minute fraction of the roles played by native nAChR
subtypes in specific functions in the human brain.
The most widely expressed subtypes in brain are the hetero-
meric α4β2-subtype and the homomeric α7 nAChRs24. These
receptors are essentially ionotropic proteins, i.e. ion channels,
whose main ability is to rapidly permeate potassium, sodium, and
calcium ions in neurons and astrocytes. It has recently been
disclosed that α7 nAChRs have an additional property45,46, namely
the ability to activate downstream metabolic cascades much like
the G-protein-coupled receptors, which constitute a structurally
and evolutionarily unrelated superfamily of receptors. This dual
functionality only found so far in the α7 nAChR, couples the
ionotropic activation elicited by the endogenous agonist ACh to
metabotropic neuronal signaling and plasticity phenomena
mediated by a G-protein-binding domain located in the intracel-
lular loop of the α7 nAChR. Thus, neuronal α7 nAChRs appear to
display both ionotropic and metabotropic properties, whereas α7
nAChR in microglia lack ion channel permeation and exhibit only
the metabotropic function, as is the case with other non-neuronal
cells, like macrophages, which operate via the JAK2/STAT3
transcription factor pathway, as reviewed elsewhere24.
The α7 nAChR, encoded by the CHRNA7 gene47, has been the
prototype of the homomeric (five apparently identical copies,
α7 × 5) type of neuronal nAChRs. Another peculiarity of the α7
nAChR is that it possesses five identical ACh recognition sites
instead of the canonical two sites of the other nAChRs:
heteromeric subtypes carry the two orthosteric agonist-
recognition sites at the interfaces between two adjacent non-
homologous subunits, one of which is an α-subunit. Gotti and
coworkers have characterized a native heteromeric α7β2 nAChR
expressed in human basal forebrain and having physiological and
pharmacological profiles different from those of the typical
homomeric α7 nAChR48 reviewed in refs. 24,49. The latter subtype
of neuronal nAChR is highly expressed in brain, particularly in
cerebral cortex, subcortical areas, and hippocampus, where it has
been associated with mechanisms of neuroprotection and the
processes of learning, memory, attention, reward, sensory
information processing, and cognition50,51.
Recent experimental work has provided new information on the
distribution of nAChRs across the different layers of the cerebral
cortex and the different functional roles played by these layer-
specific receptors, either located on dendrites of principal neurons or
on GABAergic interneurons52. An interesting finding is that the spike
timing-dependent synaptic plasticity is oppositely regulated by the
activation of nAChRs located in different cortical layers: superficial
layer 2/3 (L2/3) pyramidal neurons are inhibited by nAChR activation
on interneurons, whereas deep L6 pyramidal neurons are excited by
postsynaptic nAChRs. Thus, this stratified nAChR expression allows
functional layer-specific control of cortical processing and plasticity
by the basal forebrain cholinergic neurons. This system appears to be
evolutionarily conserved from mice to humans, the neocortex of the
latter maintaining opposite layer-specific cholinergic control of
synaptic plasticity. Different sets of cholinergic neurons located in
the basal forebrain preferentially target superficial or deep cortical
layers of the medial prefrontal cortex (mPFC)52.
Abundant layer-specific neuroanatomical representation of
these projections in brain are an important manifestation of
phylogenetic evolution; however, it is the diversity and extent of
expression of nAChR subtypes at the cellular and subcellular
levels, and the multiple combinations of subunits in this
pentameric receptor, that play a major role in the physiology
and pathology of the nicotinic cholinergic system in brain. The
correlation between layer-specific nAChR expression and func-
tional layer-specific control of cortical processing and plasticity by
the basal forebrain cholinergic neurons52 is a clear example of the
strategy developed by the brain in the course of evolution to
maximize structural–functional diversity at the cellular level. The
nine α subunits and three β subunits so far identified in the CNS
already provide combinatorial potential, which to date, however,
appears not to be fully realized in the actual brain. This repertoire
of combinatorial possibilities also determines various levels of
affinity for the neurotransmitter and cholinomimetic drugs as well
as the topographical specialization of nAChRs across the brain
architecture, the ion permeability, and various degrees of
desensitization resulting from ligand binding to different nAChR
subtypes. For instance, the α7 nAChR has an unusually fast on-rate
of desensitization, which apparently plays a functional role in the
termination of synaptic transmission mediated by this subtype of
receptors. The natural ligand, ACh, and the full agonist nicotine
trigger sodium flux through the α4β2 nAChR and calcium-
mediated currents in the case of the homo-pentameric α7 nAChR,
albeit with 100–1000 lower affinity in the latter case53.
Abnormal expression of α4β2 nAChRs has been shown to alter
cholinergic neurotransmission in neuropsychiatric disorders, includ-
ing autism spectrum disorders54,55, nicotine addiction56–60, AD61,
and Parkinson disease (PD)56. Alterations of α7 nAChR expression
have been associated with various brain disorders, interactions with
amyloid-β, and with the pathogenesis of dementia through multiple
mechanisms62–69. Expression of the α7 nAChR, which binds nicotine
with low affinity, is reduced in the hippocampus of schizophrenic
patients70. Early studies found a non-uniform decline in α7 nAChR
expression; regional specificity was suggested by the diminution of
expression in frontal cortex but not in parietal cortex71.
The experimental evidence accumulated during the last two
decades provides solid support to the notion that α7 nAChR is a
strong candidate for understanding the pathophysiology of
psychosis in both schizophrenia spectrum disorders and AD72,73.
Abnormal expression of α7 nAChR has also been associated with
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the auditory sensory gating deficit characteristically found in
patients suffering some forms of schizophrenia spectrum dis-
orders and their relatives. The typical sign is the diminished
suppression of an auditory-evoked response (P50) to repeated
stimuli. The CHRNA7 gene coding for the α7 nAChR protein has
been linked to the P50 deficit74. This finding, in conjunction with
evidence of familial transmission of this sensory gating deficit, led
to a suggested pathogenic role of the gene coding for the α7
nAChR in schizophrenia spectrum disorders75 (see also refs. 76–79
for recent reviews of genetic factors in these disorders).
Hashimoto80 has prompted the use of auditory sensory gating
as a translational biomarker.
Additional associations are found between nicotine addiction
and risk of dementia. The comorbidity of nicotine dependence is
2–3-fold higher in psychiatric patients in general, but the
association between tobacco smoking and schizophrenia is even
stronger, as shown in meta-analysis of worldwide studies: 70% of
male schizophrenic patients and 40% female patients were found
to be smokers81, a prevalence higher than for any other
psychiatric disease. Another linkage between the smoking habit
and illnesses is that smoking promotes atherosclerosis and
vascular disease increases the risk of dementia, whereas nicotine
has been shown to exert neuroprotective effects on dementia via
α7 nAChRs in preclinical studies82. Antagonists and agonists of α7
nAChRs have been found to regulate the gating or filtering of
auditory information in both humans and animal models83–87.
[H3]-nicotine binding, an in vitro biochemical readout of the high
affinity nAChRs, was also found to be lower in patients with
schizophrenia spectrum disorders and did not increase in response
to tobacco use, as observed in control subjects65. It is hypothesized
that patients smoke to alleviate cognitive symptoms57. This is taken
as evidence that nicotine enhances cognition88. The hypothesis is
still inconclusive; see recent review in ref. 89.
A recent study focuses on the relationship at the gene–gene
and gene–environment levels of the interactions between
CHRNA7 polymorphism, apolipoprotein E (APOE) ε4 carriers, and
smoking on risk of dementia. Late-onset AD (LOAD) patients and
115 vascular dementia patients were compared with healthy
individuals. Among APOEε4 non-carriers, CHRNA7 rs7179008 and
GT haplotype in CHRNA7 block4 variant carriers exhibited
significantly decreased risks. These findings suggest that there
are gene associations that up-regulate or down-regulate the risk
of vascular and non-vascular forms of dementia90.
ROLE OF MUSCARINIC RECEPTORS IN PSYCHOTIC DISORDERS
Although this review addresses primarily the role of nicotinic
cholinergic neurotransmission in delusional thinking, we will
briefly review the brain muscarinic system and the evidence that
points towards its involvement in psychotic states91–94.
Central muscarinic receptors are G-protein-coupled receptors
widely distributed in the mammalian brain. They consist of five
subtypes termed M1–M5 and called M1-like and M2-like receptors.
M1-like receptors comprise the M1, M3, and M5 receptors. These
are located post-synaptically, promoting neurotransmission when
activated by ACh. M2-like receptors comprise the M2 and M4
receptors and are located both pre-synaptically and post-
synaptically, acting mainly as autoreceptors (for detailed reviews
of the central muscarinic system see refs 95,96.
The M1 receptor is the most abundant muscarinic receptor in
the cortex, the striatum, and the hippocampus. The M3 receptor
shows a distribution which parallels that of the M1 receptor, albeit
with a lower density. The nucleus basalis of Meynert and the
occipital cortex are rich in M2 receptors. M4 receptors are
prominent within the striatum and the caudoputamen. The M5 is
the muscarinic receptor with the lowest expression levels; it is
found in the substantia nigra pars compacta and the ventral
tegmental area97–99.
The clinical entity known as anticholinergic delirium observed in
patients treated with anticholinergic drugs suggests that muscarinic
receptors are implied in these psychotic phenomena100–102.
In 1972, Janowsky and coworkers advanced a
cholinergic–adrenergic hypothesis of mania and depression103.
The authors proposed a balance between cholinergic and
adrenergic neurotransmission in those areas of the brain involved
in affective regulation. They briefly mention the exacerbation of
schizophrenic symptoms in patients exposed to organopho-
sphates104, suggesting a muscarinic cholinergic receptor mechanism
after cholinesterase inhibition. Due to increased ACh at the synaptic
cleft in multiple brain areas after organophosphate exposure, it is
difficult to discriminate between muscarinic and nicotinic receptors
in the production of this exacerbated symptomatology.
A more direct involvement of muscarinic receptors in the
production of psychosis (in this case negative symptoms of
schizophrenia) was advanced by Tandon and Greden105. Positive
symptoms of schizophrenia are explained by increased mesocor-
tical and mesolimbic dopamine but a compensatory increase in
cholinergic mechanisms is operative in the production of negative
symptoms such as alogia, avolition/apathy, anhedonia, and
attentional deficits105. This involvement of cholinergic mechan-
isms and more specifically of muscarinic receptors is supported by
a study that shows amelioration by the anticholinergic agent
trihexiphenidyl of negative symptoms in schizophrenia patients.
Trihexiphenidyl binds to the M1 muscarinic receptor106. This may
partially explain the elevation in mood, better socialization, and
stimulation effected by trihexyphenidyl in this patient population,
often subsequently leading to abuse of this medication107. The
effect is also observed in neuroleptic-naïve patients indicating a
beneficial effect beyond relief of extrapyramidal side effects105.
The evidence for involvement of muscarinic receptors in
schizophrenia spectrum disorders is supported by post-mortem,
pharmacological, and imaging studies94. In this respect, an
important study by Bakker and collaborators108 was able to show
a correlation between a reduced binding potential of M1 receptor in
the dorsolateral prefrontal cortex, a key area involved in the
production of negative symptoms in schizophrenia spectrum
disorders. The study was conducted on medication-naïve psychotic
patients and used single-photon emission computed tomography
with a specific radioligand that measured binding potential of M1
receptors108. The authors were able to show a correlation between
lower binding potential of the M1 receptor and poor outcomes in
several neurocognitive tests and negative symptoms severity.
However, there was no mention of delusional thinking.
In conclusion: it is clear from the published evidence regarding
the involvement of muscarinic receptors in psychosis, specifically
in schizophrenia spectrum disorders, that these receptors are
related to cognitive deficits in attention, working memory,
concentration, and executive functions91,93,108, which in turn
translate into negative symptoms, and in neurological soft signs57.
Although short-lived delusional thinking is certainly a feature of
anticholinergic delirium produced by antimuscarinic drugs101,102,
it is not clear how muscarinic receptors participate in the genesis
and ulterior maintenance of both well-crystallized and system-
atized delusional thinking.
CHOLINERGIC PATHWAYS IN THE BRAIN
The cholinergic system consists of subcortical as well as cortical
domains, organized into two main pathways: (i) the brainstem and
(ii) the magnocellular basal forebrain cholinergic system109.
There are two cholinergic nuclei in the brain, as well as a high
concentration of cholinergic interneurons in the basal ganglia.
Interactions between cholinergic interneurons and dopaminergic
neurons in the basal ganglia are well characterized. The striatum
contains extremely high concentrations of ACh relative to other
areas in brain, the main locus being in the cholinergic
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interneurons, specifically in the dorsal striatum (caudate nucleus
and putamen), which however constitute only 1–2% of all the
striatal cellular content. The mesocorticolimbic system connects
the neurons of the ventral tegmental area (VTA) with the nucleus
accumbens (NAc, in the ventral striatum) and the prefrontal cortex
(PFC). The experience-dependent dopamine neurons in the VTA
are key elements in the regulation of the brain reward system,
whose dysregulation is associated with depression and mood
disorders110,111. Excitatory glutamatergic/cholinergic inputs in
dopaminergic neurons, as well as inhibitory GABAergic afferents
on these cells, are modulated by nAChRs present in cholinergic,
glutamatergic, and GABAergic terminals. A direct activation of
excitatory postsynaptic nAChRs results in depolarization and firing
of dopaminergic neurons111.
In addition, an indirect mechanism involving α7 nAChRs triggers
glutamate release in glutamatergic synapses, which in turn elicits
activity of dopaminergic neurons in the VTA112.
ACH’S ROLE IN DELUSIONS IN ALZHEIMER DISEASE (AD)
Forty-one percent of persons with AD experience hallucinations
and delusions early in the course of the disorder113. The
occurrence of these symptoms is associated with faster cognitive
decline114. Of particular relevance to this review, psychotic
thinking consists mainly of persecutory and misidentification
delusions115. Cholinergic deficits are implicated in the genesis of
cognitive and psychotic symptoms in AD116, and these deficits
have been associated with α7 nAChRs in both schizophrenia
spectrum disorders and AD72–75,84,85,117,118. Furthermore, the gene
coding for the α7 nAChR (CHRNA7) is known to be associated with
symptoms of schizophrenia spectrum disorders in linkage and
association studies47,119. More specifically, a strong correlation
between delusional thinking in AD and a C/T polymorphism
located in intron 3 of CHRNA7 was reported by Carson and
coworkers72. Delusional symptoms (mainly of the persecutory and
misidentification types) were more pronounced in patients
homozygous for the T allele than for the CC or the CT genotypes72.
Cholinergic brain pathways are implicated in cognitive pro-
cesses57,120. The best example is the cognitive decline seen in
patients with AD dementia, which is correlated with early
degeneration of ACh-synthesizing neurons in the subcortical
nuclei of the human basal forebrain121–123. New evidence suggests
that the cholinergic system may be implicated not only in
cognitive deficits but also in the development of psychotic
symptoms in this patient population10,101,124.
A biochemical study examining regions of interest in post-
mortem brains of patients with Lewy body dementia found an
elevated M1-subtype of muscarinic ACh receptor concentration in
the fusiform gyrus of the temporal lobe125; this type of receptors
has not been found on dopaminergic neurons in the stria-
tum110,123. In relation to this observation, it is instructive that the
relationship between muscarinic tone and psychosis is reversed in
schizophrenia spectrum disorders, where decreasing muscarinic
tone is associated with increasing psychosis126 and agonism with
decreasing psychosis127. Although the exact mechanism of action
by which cholinergic deficits produce psychosis in AD is not
known, imaging studies show that psychosis is associated with
abnormalities in frontal and temporal cortices where cholinergic
deficits are more pronounced124. The same brain areas show
increased M2-type muscarinic receptor binding128, suggesting
participation of these receptors in psychosis. It has been
suggested that deficits in pathways involving muscarinic receptors
abnormally facilitate dopaminergic systems producing psycho-
sis129. Blockade of cholinergic circuits can produce psychosis, as
seen in patients treated with anticholinergic drugs102. Antic-
holinergic drug-induced delirium, another example of psychosis
seen in clinical settings, manifests with frank delusional think-
ing124. Drugs that enhance cholinergic transmission, such as
cholinesterase inhibitors, decrease delusions and hallucinations in
AD patients130,131.
ACH IN SCHIZOPHRENIA SPECTRUM DISORDERS
The relationship between nicotinic signaling and schizophrenia is
complex, given the number of subunit combinations of this
neurotransmitter receptor possibly involved and their distribution
within the central nervous system. However, although the
involvement of nicotinic signaling in the general cognitive decline
in schizophrenia spectrum disorders is clear57,120,132, as is its
potential to modestly improve cognition, this alone is insufficient
to suggest participation of the nicotinic type of neurotransmission
in delusions, as there is no consensus on the relationship between
cognitive deficits of schizophrenia and the genesis and main-
tenance of delusional thinking133,134. It is also clear that a4β2
receptors are specifically upregulated in the striatum in smokers in
general but not at all or at least not to the same degree in smokers
with schizophrenia spectrum disorders135,136.
In connection with the dopaminergic hypothesis of psychosis,
research on addiction has shown that nicotine drives a much
greater increase in phasic signaling by DA in the NAc than in the
dorsal striatum which contains the caudate nucleus and puta-
men137; furthermore, it has been shown that there is a reduced
density of cholinergic interneurons in the ventral striatum in
schizophrenia spectrum disorders138,139. The NAc expresses α6
subunit-containing nAChRs, rather than the α4 subunit-containing
receptors that constitute the majority of dorsal striatum
nAChRs140. Notably, a consistent finding has been that of nicotine
serving the role of reinforcing reward rather than affecting the
dorsal striatum where the putative central cognitive pattern-
generating striosomes reside (see Fig. 1). This is consistent with
nicotine being addictive but having no effect on positive
symptoms and with its documented effect on mesolimbic circuitry
and brain regions associated with reinforced behavior, rather than
feedback-insensitive behaviors like those produced by central
pattern generators. Mesolimbic modulation is also consistent with
improvement in the negative symptoms sometimes seen with
nicotinic agonism141 but not in positive symptoms. α7 nAChR
agonists have also been shown to improve both negative
symptoms and cognition in schizophrenia spectrum disorders142.
Notably, it has been shown that cholinergic interneurons in the
dorsal striatum are responsible for this modulation143. Further-
more, the linkage of α7 nAChRs (widely distributed in cortex) with
schizophrenia spectrum disorders has been established for some
time by GWAS studies88.
The model proposing dopaminergic projections from the VTA
to the ventral striatum (the mesolimbic circuits) is no longer well-
supported, as shown by the meta-analysis of positron emission
tomography (PET) data and a review of all available imaging and
anatomic data144,145. A more likely picture is the central
involvement of dysfunction of the nigrostriatal circuits which
make synaptic contacts with striosomes in the dorsal striatum.
Striosomes are histochemically recognizable striatal compart-
ments within the striatum146–148 and will be a key region to
further discuss in terms of their putative involvement in delusional
thinking (see Figs 1 and 2).
Cholinergic neuronal cells represent only 2% of cells in the
striatum but appear to establish synapses on a large fraction of
striatal cells149. There is anatomical and pharmacologic evidence
for this role. By identifying cells in the striatum with choline
acetyltransferase (ChAT) immunoreactivity, it was shown that they
are most frequently found in the periphery of striosomes where
they are ideally positioned to modulate nigrostriatal dopaminergic
inputs; there are far fewer in the putamen150. Muscarinic M4-
agonism alleviates the amphetamine model of psychoses in
rodents, with the dorsal striatum as a preferential target127. It has
been shown that medication-naive patients with schizophrenia
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spectrum disorders have reduced levels of muscarinic receptors,
particularly in the striatum, as to be expected in individuals having
difficulty adapting to uncertainty and rapidly updating beliefs126.
Striosomes are the most likely central pattern generators, e.g.
responsible for species-specific stereotypies. If some delusions are
indeed cognitive stereotypies arising from hyperfunction of
striosomes functioning as cognitive central pattern generators,
we can make strong inferences and predictions about the
behavior of delusions under various experimental manipulations
(see Fig. 3). Stereotypies are well known to be intensified or
prolonged by increasing dopaminergic input to, or tone in, the
striatum, for example in amphetamine paradigms, both experi-
mentally and in stimulant abuse in humans. Increasing cholinergic
transmission in the dorsal striatum stops stereotypies more
quickly; decreasing cholinergic transmission by blocking post-
synaptic receptors with muscarinic antagonists increases the
length of stereotypies151 and striatal cholinergic interneurons
modulate hyperdopaminergic dyskinesias152.
This picture is complicated by the differential function of
muscarinic and nicotinic receptors. In the striata of patients with
schizophrenia spectrum disorders there are fewer M1-type
muscarinic receptors153. M1 receptors are not located on
cholinergic interneurons and they do not serve an autoreceptor
function154. However, there are presynaptic non-M1 receptors on
cholinergic interneurons154. There is also greater nicotine binding
in schizophrenic patients, presumably on the postsynaptic target
neurons155. One would therefore expect that increasing muscari-
nic or decreasing nicotinic neurotransmission would improve
patients suffering from delusions. The striatum is primarily
composed of two classes of spiny projection neurons (SPNs): the
striatonigral and striatopallidal SPNs, which express D1R and D2R,
respectively. Within striosomes there are more D1R-expressing
than D2R-expressing SPNs, whereas in the matrix there are more
D2R-expressing than D1R-expressing SPNs (Figs 2 and 3).
ACH IN DELUSIONAL ILLNESS: PD
Psychosis is a non-motor and late complication of PD. It predicts
Lewy body pathology in the brain cortex156 and shows a variable
response to antipsychotic agents. In fact, psychosis in PD presents
with marked heterogeneity suggesting the involvement of multi-
ple neurotransmitter systems in its genesis. Recently, Factor and
coworkers were able to delineate multiple subtypes of PD
psychosis157. Delusions are present in about 6–16% of patients,
with Othello syndrome, grandiose, religious and guilt types being
the most frequent forms of delusion157.
Fig. 1 Schematic diagram of the striatum, its various input
pathways, and the beginning of the well-characterized direct and
indirect output pathways. Striosomes are the site of integration of
input from the substantia nigra pars compacta (SNc), thalamus, and
cortex, and are prime candidates for the central cognitive pattern
generators whose dysfunction may underlie delusions. The matrix,
composed primarily of cholinergic interneurons, surrounds the
striosomes and modulates input. Output from the striatum is
through medium spiny neurons which target the internal globus
pallidus (GPi) or the external segment of the globus pallidus
(GPe) and eventually, the thalamus146,147.
Fig. 2 Detail of the striosome. Dopaminergic inputs are received
from the SNc and glutamatergic inputs from the cortex and
thalamus. The cholinergic system has a key role in the integration
of these signals, which are modulated by cholinergic interneurons in
the matrix surrounding the striosomes, and output is mediated by
medium spiny neurons, which are GABAergic neurons forming the
direct and indirect pathways (thick vertical arrows) depicted here
and in Fig. 1. See also refs 146,147,230.
Fig. 3 Detail of the most relevant synaptic contacts within the
striosome on medium spiny neurons. While it is not a compre-
hensive diagram of all receptors or all interactions between these
neurons, the diagram is intended to highlight the inputs from the
cholinergic interneurons, as well as the cortex, thalamus, and
substantia nigra pars compacta (SNc), all converging on the medium
spiny neuron. Importantly, here is where ACh exerts its effect on
prediction error, modulating prediction error by boosting bottom-
up signals.
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The exact mechanism of delusional symptoms in PD patients is
still obscure and is not explained by current ideas on the
development of psychosis in these patients158. However, the role
of the cholinergic system in PD is made clear by the finding of a
strong, statistically significant correlation between hallucinations
(but not delusions) and freezing of gait159, both coexisting with
cognitive decline. Cholinergic mechanisms are involved in the
development of hallucinations160 but, interestingly, delusions are
not associated with cognitive decline161 and some patients present
with pure delusional syndromes in the absence of perceptual
disturbances162,163. The development of delusions does not appear
to have a cholinergic basis, is related to dopaminergic medications,
and is reversible upon discontinuation of the offending drug164.
ACH IN OTHER NEUROPSYCHIATRIC ILLNESSES
It should be noted that although the pathophysiology of delirium
is thought to rely on a disturbance in cholinergic neurotransmis-
sion165, given the acuity and rapid course of the illness and
medical fragility of those suffering from it, there is a dearth of
imaging studies directly examining this question and certainly in
looking at the specific pathogenesis of delusions in this
condition166,167. It is intriguing that there is a case report of a
patient with delirium secondary to a urinary tract infection
developing a Capgras delusion, presumably as part of delirium,
which resolved in days with the cure of the organic illness168.
THE NEURONAL CELL AND CIRCUITRY LEVELS
Huntington disease
The occurrence of neuropsychiatric symptoms in HD, including
positive symptoms of psychosis, is common169 and generally
under-appreciated. While almost all HD patients develop neurop-
sychiatric symptoms during their illness, a recent survey found
that psychosis is the presenting feature in 11% of cases and that
delusions occurred in 11.5% of patients170. Obsessive compulsive
symptoms are more common than delusions171, consistent with
the theory of striosomal hyperfunction as underlying both
cognitive stereotypies (obsessions, delusions) and motor beha-
viors, as in obsessive compulsive and tic disorders. It is also curious
that, similar to patients with psychosis, HD patients often have
poor insight into their deficits, both cognitive and motor172.
The etiogenesis of HD is well characterized173, with the
expansion of a trinucleotide repeat in the Huntington gene,
causing a toxic gene product to accumulate in and cause selective
death of the GABAergic medium spiny neurons, making psychotic
symptoms difficult to explain in terms of the dopaminergic model
of psychosis. These neurons constitute the majority of cells in the
caudate174. As a result, as the disease progresses the classic
finding is radiologically visible atrophy of the caudate heads,
although post-mortem studies typically show degeneration in
many brain regions175–178. While in terms of cell count, cholinergic
interneurons are spared, ChAT levels drop, suggesting dysfunction
of these cells179. Consistent with the current model of the
computational function of striatal cholinergic interneurons, with
decreasing activity of these cells we should expect an intensifica-
tion of stereotypies and rigid beliefs. Therefore, a test of the
cholinergic neurotransmission aspect of the striosomal hypothesis
of delusions would be to investigate the association between the
extent or distribution of ChAT loss and the onset or intensity of
psychiatric symptoms including delusions; to the best of our
knowledge no such data is available as yet. Similarly, delirium and
many dementing illnesses are canonically considered to be
disruptions in ACh signaling. To our knowledge, there has been
no attempt to link ACh signaling directly in the basal nuclei, and
the caudate in particular, to the severity of the pathology in these
illnesses, including delusions. Given the increasing importance of
this nucleus in neuropsychiatric illness and the argument here for
its role in delusion, this aspect should be further explored.
ACh and prediction error
A great deal of what we know about cognitive approaches to
understanding delusions has been pioneered by the work of
Corlett12–16. Brains are inference engines which construct hypoth-
eses to predict or interpret stimuli (“top-down” processing), and
when there is a discrepancy between prediction and perception,
generate an error message (a prediction error signal, “bottom-up”
processing)180,181, see review in ref. 182. This Bayesian (probabil-
istic) inference mechanism is understood to be defective in
various forms of psychoses, particularly in schizophrenia spectrum
disorders, either because of abnormal signaling of the prediction
errors, abnormal sensory inputs, or both, ultimately resulting in
dysfunctional predictive coding. Applying this concept to the
empirical dysfunction observed in delusional illnesses may show
where this computation is instantiated and ultimately suggest
corrective measures that could be used in therapeutic approaches.
Thus far, research on the prediction error signal has largely
focused on glutamatergic or dopaminergic neurotransmission.
Predictive coding has been associated with gain of control of
postsynaptic glutamatergic excitatory transmission mediated by
NMDA receptors and dopaminergic neuromodulation180. How-
ever, as schematically depicted in Fig. 3, ACh has an important role
in modulating this signal; the behavior of VTA circuitry is explained
by a computational model showing that the endogenous
neurotransmitter ACh and the exogenous full nicotinic agonist
nicotine both effectively desensitize nAChRs and cause increased
reward signals, i.e. decreasing ability to predict reward183. These
effects are mediated by α4β2 nAChRs on GABAergic neurons
acting on dopaminergic neurons—also containing α4β2 nAChRs
on their surface—in the VTA (reviewed in ref. 183). This has been
demonstrated in an experimental paradigm using galantamine
application in combination with EEG measurements, by showing
that ACh boosts bottom-up prediction errors, which are preferen-
tially observed under conditions of increased uncertainty184,185. In
this way the brain’s purported hierarchical Bayesian prediction
function can be tuned to increase input from top-down or
bottom-up data, for optimal predictions under varying condi-
tions186. It is intriguing that one of the hallmarks of delusional
ideation is pathologic conviction (certainty when it is not justified),
especially as it relates to the striosomal hypothesis of delusions.
Yamanaka and coworkers argue that thalamostriatal neurons
project to striatal cholinergic interneurons, and that this system
generates an “associability” signal, the certainty of which is
modulated by cholinergic neurotransmission187. It is known that
dopamine release from these thalamocortical projections is tonic
and suppresses firing of striatal cholinergic interneurons, but the
significance of this in the context of illness is unclear188.
It is not clear whether ACh can be accurately measured by
magnetic resonance spectroscopy (MRS) in awake subjects. MRS
allows the measurement of molecules in the brain by detecting
the specific magnetic fields of protons as they are shifted by
moieties in those molecules. While two neurotransmitters
(glutamate and GABA) can be accurately and reliably measured,
neurochemical and technical difficulties have so far made this
challenging for ACh. First, it is the choline moiety (not the full ACh
molecule) that is detected, and a substantial fraction (likely the
majority) of this signal can be assumed to come from free choline
being used for cell membrane biosynthesis. Second, there is less
ACh present than the two other neurotransmitters mentioned,
and this worsens the signal to noise ratio. Nonetheless, in rat,
MRS-measured choline was shown to correlate with directly
(chemically) measured ACh189. However, functional changes may
not be measurable, as task-driven changes in MRS-measured
choline were similar to the presumed unrelated metabolite
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N-acetyl-aspartate, suggesting that dynamic MRS measurements
may still not be sufficiently sensitive and/or reliable190.
Linking up with the framework of Bayesian reasoning and
prediction error, it has been argued that ACh modulates
prediction error signals and tunes the brain’s updating in response
to varying degrees of uncertainty. That is, in predictable
environments, ACh enhances bottom-up signaling (to enhance
the salience of sense data) and in unpredictable environments, it
dampens it. This model is experimentally supported by increased
sensory cortex response in an oddball paradigm with human
subjects taking galantamine184. Galantamine also increases the
rate of updating in a spatial beliefs model (using an eye-tracking
paradigm)185. Consequently, a hypocholinergic state would be
expected to slow belief updating (as in delusional belief) and an
increase in cholinergic tone would improve it, as shown with
galantamine191. Acetylcholinesterase inhibitors (which increase
ACh neurotransmission) have been used off-label to improve
cognition in schizophrenia192–195. The obvious inference is that
the decreased cholinergic neurotransmission, consistent with
what is seen in α7 nAChR loss-of-function mutations in animal
models, would result in decreased ability to adapt to environ-
ments based on predictability and consistent low weight placed
on unexpected data in predictable environments, relative to top-
down beliefs. Cognitively, this could be envisioned as someone
who is convinced of the predictability of the world despite sense
data inconsistent with this belief.
An additional role of ACh is worth mentioning. In a seminal paper,
Moran and coworkers showed that ACh is a neuromodulatory
transmitter involved in perception and learning under uncertainty184.
Using computational simulations and electroencephalography the
authors suggested that ACh enhances the precision of bottom-up
synaptic transmission, optimizing the gain of pyramidal cells184,185.
A UNIFYING HYPOTHESIS: DELUSIONS ARE IN PART CAUSED
BY HYPERDOPAMINERGIA AND OVERACTIVE STRIOSOMES IN
THE DORSAL STRIATUM, MODULATED BY CHOLINERGIC
INTERNEURONS
One shortcoming of delusion theories thus far is the minimal
effort taken to explain the specificity of polythematic content, with
delusion being clustered into predictable themes across cultures.
The dopamine theory of psychosis is well-established; dopamine
blockade improves positive symptoms and dopamine agonists
induce or worsen positive symptoms. What remains under-
appreciated is the anatomy of dopamine modulation in psychosis,
with recent evidence pointing toward the nigrostriatal dopami-
nergic pathway and focusing on the dorsal striatum as relevant in
the production of psychotic symptoms145. Specific models of
delusional belief show that changes in activity in the dorsal
striatum as observed with fMRI correlate with the amount of
delusional ideation in illness196.
One argument for the source of delusional themes advances
striosomes as the explanation for the content of delusions148,
conserved as they are cross-culturally, strongly suggesting a
biological basis. As illustrated in Figs. 1–3, striosomes are clusters
of specialized neurons within the caudate which receive
dopaminergic projections from the substantia nigra pars com-
pacta148. Striosomes are known to be responsible for specific
motor programs (stereotypies) which have clear evolutionary
importance and are not subject to modification and are highly
reward-insensitive. For example, individual striosomes in rodents
have been isolated and shown to be responsible for specific
stereotypies, e.g. parts of the grooming chain197. The basal ganglia
are evolutionarily older than the cortex and off-loading repetitive,
evolutionarily important actions makes economic sense for the
brain. Dopamine agonism has been shown to cause growth in
the striosomes, the degree of which in turn is correlated with the
increase in stereotypy frequency198,199.
While thus far striosomes have only been shown to be responsible
for motor programs in non-human animals, it is speculated that in
humans they may also be responsible not only for stereotypies, but
also for cognitions which are of similar evolutionary importance and
reward-insensitive. The fit with delusional themes is immediately
apparent—for instance, identification of conspiring competitors,
possible mates, or cheating on one’s own mate. Furthermore,
delusions are responsive to dopamine blockade or agonism, and in
other illnesses like OCD or Tourette syndrome, there is a clear
crossover between repetitive motor and cognitive patterns200. Some
of the themes of OCD overlap with delusions and indeed sometimes
there is damaged, but not absent, insight, making diagnosis difficult
and resulting in discussion at one time about adding a schizo-
obsessive diagnostic category to DSM201,202. Tourette is a related
illness with a specific reward-insensitive behavior that often
responds to antipsychotics. In cases where it does not, the nicotinic
antagonist mecamylamine has been found to sometimes be
effective203. The argument is strengthened by our increasingly
detailed knowledge of the complex architecture of the dorsal
striatum, with considerable evidence that matrix and striosome
respond differently to the same inputs147,204. There are differences
depending on nicotinic receptor subtype within the striosomes, and
differential activation may be what drives fixed motor pattern
(stereotypies)205. The role in aberrant movement of dopaminergic
hyperstimulation of the dorsal striatum and its modulation by
cholinergic inputs has been well-established152. In fact in mice with
amphetamine-induced stereotypies and poor response to environ-
mental cues, direct electrophysiology shows that cholinergic
modulation of striosomes is disrupted, again suggesting that ACh
in the dorsal striatum serves to increase sensitivity to bottom-up
information and thus predispose to belief updating. This has an
obvious parallel in amphetamine-induced psychosis in humans, as
humans develop tics and stereotypical behaviors in response to
intoxication with dopamine agonists206. If as has previously been
argued207 we can extend the animal models of striosome-originated
stereotypies to delusions, taking stereotypies as rigid behaviors, a
kind of “motor delusion” (or considering delusions as “cognitive
stereotypies”), then this would explain the neuroanatomy under-
lying delusions in psychosis and dopamine agonist intoxication. The
striosomal model therefore argues that the specific themes of
delusions (specificity), and their insensitivity to new information
(conviction) is the result of hyperdopaminergic, over-driven strio-
somes. It should also be noted that computational studies of
cognition have noted attractor basin-like dynamics demonstrated by
delusion formation208, and striosomes are an excellent candidate for
the physical instantiation of this phenomenon.
In terms of neurotransmission, it is suggestive that the highest
concentration of ACh in the brain is in fact in the dorsal
striatum209, and given the role of this neurotransmitter in
modulating striatal prediction error, one would expect cholinergic
antagonism to worsen delusions, which in fact is what is observed,
particularly in delirium and AD dementia, as well as in some cases
of Huntington and iatrogenic psychoses. Thus, the striosomal
theory of delusional content accounts both for the dopamine
theory of psychosis, and deviations from the model where the
disturbance is cholinergic.
It should be noted that the dorsal striatum accounts for only
part of the hypothesis; namely, the specificity of polythematic
delusions. The poor insight present in delusions, as well as somatic
and misidentification delusions, very likely result from functional
lesions of the right frontal lobe. Indeed, that somatic or
misidentification delusions (e.g. Capgras syndrome) result from
lesions of the right frontal lobe is one of the best supported
observations about the anatomy of delusions so far210,211. Given
these putative roles, it may be the case that a right frontal lesion
without striosomal hyperfunction results in somatic delusions,
whereas striosomal hyperactivity in the dorsal striatum occurring
without right frontal deficits would induce thematically specific
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cognitive or motor behaviors, with preserved insight, conditions
that are worsened by dopamine agonists and improved by
dopamine antagonists. This is a description of OCD and Tourette
syndrome, which we know involve disruptions to striatal signal-
ing212 and often respond clinically to dopamine blockade.
It is important to note that the cognitive approaches for
understanding delusional thinking using a two-factor hypothesis,
mainly proposed by Corlett12–16, have been recently revisited by
this author213.
New directions for investigating and treating delusions
Over the past two decades there has been a focus on developing
cholinergic (especially nicotinic) modulators for schizophrenia
spectrum disorders and AD that have yielded inconsistent
results214, as well as case reports with acetylcholinesterase
inhibitors193,215. It may be that the best role for such molecules
is as an adjunct, given the cholinergic system’s role in modulating
uncertainty and updating, while dopamine is more central to the
etiology of psychosis. Recent pharmacological evidence has
provided new insights into our understanding of cholinergic
signaling in brain and have put the α4β2 and the α7 nAChRs in a
center-stage position as possible targets for therapeutic interven-
tion in neuropsychiatric diseases with cognitive deficits including
autism spectrum disorders, nicotine addiction, schizophrenia
spectrum disorders88, AD, and PD56,216–218. For instance, rivastig-
mine, a drug that increases cholinergic tone by inhibiting the
enzyme cholinesterase, is effective for dementia, whereas the use
of Donepezil is still in the realm of investigation218. Activation of
the α7 nAChRs by selective ligands enhances cognition in
schizophrenic and AD patients74,84,85,219.
Another set of compounds gaining momentum is the wide
spectrum of allosteric modulators, new leads as therapeutic
agents for the treatment of neuropsychiatric diseases with
cognitive deficits220. These ligands exert their action in the
presence of the endogenous agonist, and by definition do not
target the canonical (“orthosteric”) nAChR agonist or competitive
antagonist recognition sites on the receptor molecule, but bind to
distant, non-orthosteric, allosteric sites which nonetheless affect
the response of the orthosteric site. There are essentially two types
of allosteric modulators, most widely studied for the α7 nAChR,
which either potentiate (positive allosteric modulators, “PAMs”) or
inhibit (negative allosteric modulators, or “NAMs”) the response of
agonist binding to the orthosteric site221–223. A third type of
compounds corresponds to the “silent” allosteric modulators
(“SAMs”), which inhibit the PAM responses without affecting the
orthosteric responses. Some authors include a fourth category,
namely the allosteric agonists, but clearly these should not be
classified as modulators: they are agonists which bind not to the
orthosteric but to the allosteric site. Presumably, endogenous
allosteric modulators occur in brain. In animal studies, PAMs acting
on α7 nAChRs, like PNU-120596 and galantamine, have been
shown to enhance performance in various cognitive and
recognition memory tasks224. The prevalent effect of PAM
compounds is to increase the probability of the nAChR channel
open state, thereby increasing its lifetime and the number of open
channel events225. Furthermore, the PAM compounds CCMI,
PNU120596, and A582941 reverse the sensorimotor gating
impairment evoked by MK-801 based on the pre-pulse inhibition
of the startle response, thus showing a beneficial effect on
sensorimotor gating and some aspects of cognition226.
There is also a great wealth of data on clinical and preclinical
observations where muscarinic receptors are targeted. The most
conspicuous of these muscarinic agents is xanomeline227 and
orthosteric muscarinic ACh receptor agonist which binds to M1 and
M4 receptors. It has proven efficacy in reducing psychotic symptoms
in schizophrenia228 and AD229, including an effect on delusional
thinking. Recently, xamomeline has been used in conjunction with
tropsium, a peripheral muscarinic antagonist in hospitalized patients
with schizophrenia that experience an exacerbation of symptoms.
This was a randomized, double-blinded, placebo-controlled Phase-2
trial (clinicaltrials.gov, NCT03697252).
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